Analysis of the expression of IFIT4, PRKR in different types hepatic involvement in systemic lupus erythematosus
10.3760/cma.j.issn.1007-7480.2012.05.005
- VernacularTitle:干扰素诱导蛋白4蛋白激酶在不同类型系统性红斑狼疮肝损害中的表达研究
- Author:
Min LI
;
Yi LIANG
;
Xiaohui WU
;
Hao WEI
;
Wenjing YU
;
Nanping YANG
;
Xiangyang HUANG
- Publication Type:Journal Article
- Keywords:
Lupus erythematosus,systemic;
Liver deteriment;
γ-glutamyl transpeptidase;
Alkaline phosphatase;
Transaminase;
IFIT4;
PRKR
- From:
Chinese Journal of Rheumatology
2012;16(5):305-308
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the expression of IFIT4,PRKR and investigate the clinical and immunology features of different types of liver involvement in patients with systemic lupus erythematosus (SLE).Methods Clinical data of 62 cases of SLE with liver damage and 62 cases of SLE without liver damage were collected.Peripheral venous blood samples were obtained and total RNA were extracted and transcribed into cDNA.Sybr green dye based real-time quantitative PCR method was used to compare the expression levels of IFIT4,PRKR in patients with SLE.Clinical parameters were analyzed by ANOVA,Chi-square test,Pearson's or Spearman's test.Results ① The increase of γ-GT or ALP was correlated with rash and oral ulcer (x2=5.625,P=0.018),lupus nephritis (x2=5.631,P=0.019),anemia,thrombocytopenia (99±21,P=0.028; 81±45,P=0.004,),CRP (33±43,P=0.004).The positive rate of nRNP (x2=4.862,P=0.027 ) and SSA (x2=8.087,P=0.004) was higher in patients with liver damage than other groups; ② The positive rate of anti-Rib antibody in SLE with liver damage was significantly higher than SLE without liver damage (x2=19.542,P=0.000); ③ There was no difference in the expression of IFIT4 among these groups,but higher expression of PRKR was detected in the group of patients with increased γ-glutamyl transpeptidase (γ-GT) or ALP(F=3.54,P=0.018).Conclusion The different types of liver damage in SLE patients have different clinical and immunology characteristics.The expression of PRKR is higher in patients with increased γ-GT or ALP.
